MGMT and neoplasm: Stratifying patients according to their MGMT promoter methylation status showed that in MGMTneg tumors, there was no benefit of tumor-specific therapy over BSC regarding PFS (logrank: in months, 3.4 versus 3.5; HR 0.76; 95% CI 0.38–1.5; p = 0.43) or OS (logrank: in months, 3.6 versus 3.7; HR 0.61; 95% CI 0.3–1.26; p = 0.18) (Fig. 2).